Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palonosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 10/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palonosetron SCHEMBL29402278 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL4058558 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL2989775 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL7782594 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL7277880 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL10066801 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL13240607 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL4052980 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3747 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3746 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11029 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260130929-A1 | USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST | SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4727627-A1 | AEROSOL-GENERATING DEVICE WITH IMPROVED AIRFLOW | Alexza Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| US-20260097042-A1 | COMPOUND EMULSION, PREPARATION METHOD THEREFOR, AND USE THEREOF | QILU PHARMACEUTICAL CO LTD (CN) | 2026-04-09 | — | — | US | claimed |
| EP-4719552-A1 | INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | ASTELLAS PHARMA INC (JP) | 2026-03-12 | — | — | US | claimed |
| CN-1355698-A | Compound for medicine for treating function of bronchial contraction | RESPIRATORIUS AB (SE) | 2002-06-26 | — | — | CN | claimed |
| WO-2002041918-A2 | USE OF A TRIPLE COMBINATION COMPRISING A 5HT3 ANTAGONIST, A 5HT4 AGONIST AND A LAXATIVE FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-30 | — | — | WO | claimed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| US-5202333-A | Tricyclic 5-HT3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 1993-04-13 | — | — | US | claimed |